Logo

Intas Signs an Exclusive License & Supply Agreement with Axantia for Ranibizumab Biosimilar to Treat Eye Disorders

Share this

Intas Signs an Exclusive License & Supply Agreement with Axantia for Ranibizumab Biosimilar to Treat Eye Disorders

Shots:

  • Under the terms of the agreement, Axantia will be responsible for registration & get the commercialization rights of Intas’ ranibizumab biosimilar referencing Lucentis in territories inc. Saudi Arabia, Jordan, Iraq, Lebanon & GCC countries through its pharmaceutical subsidiaries, pharma international pharmaceutical & chemical manufacturing, and Med City pharmaceutical industries
  • Intas' Ranibizumab biosimilar is currently under the P-III trial while Intas plans to submit for approval in the EU and the US
  • Ranibizumab is a recombinant humanized IgG1 mAb fragment that binds to & inhibits VEGF-A. It is used for the treatment of wet AMD, RVO, DME, DR, and mCNV

Ref: PR Newswire | Image: Intas

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions